These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22508745)

  • 1. ACP Journal Club. Radiation plus androgen deprivation therapy reduced mortality in locally advanced prostate cancer.
    Canfield SE; Dahm P
    Ann Intern Med; 2012 Apr; 156(8):JC4-05, JC4-04. PubMed ID: 22508745
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Review: Androgen deprivation therapy does not increase CV mortality in prostate cancer.
    Canfield SE; Dahm P
    Ann Intern Med; 2012 Apr; 156(8):JC4-04, JC4-05. PubMed ID: 22508744
    [No Abstract]   [Full Text] [Related]  

  • 3. Locally advanced prostate cancer: effective treatments, but many adverse effects.
    Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACP Journal Club. Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer.
    Stockler MR
    Ann Intern Med; 2013 Jan; 158(2):JC9. PubMed ID: 23318343
    [No Abstract]   [Full Text] [Related]  

  • 5. ACP Journal Club. Continuous androgen-deprivation therapy increased risk for diabetes and fragility fractures in older men with prostate cancer.
    Hajdenberg J
    Ann Intern Med; 2009 Dec; 151(12):JC6-14. PubMed ID: 20008750
    [No Abstract]   [Full Text] [Related]  

  • 6. ACP Journal Club. Adding radiotherapy to endocrine therapy improved survival in locally advanced prostate cancer.
    Hajdenberg J
    Ann Intern Med; 2009 Jun; 150(12):JC6-6. PubMed ID: 19528551
    [No Abstract]   [Full Text] [Related]  

  • 7. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
    Akaza H
    BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.
    Herr HW; O'Sullivan M
    J Urol; 2000 Jun; 163(6):1743-6. PubMed ID: 10799173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS; Ryan CW; Jung LL
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of androgen suppression in the treatment of prostate cancer.
    Bolla M; de Reijke TM; Van Tienhoven G; Van den Bergh AC; Oddens J; Poortmans PM; Gez E; Kil P; Akdas A; Soete G; Kariakine O; van der Steen-Banasik EM; Musat E; Piérart M; Mauer ME; Collette L;
    N Engl J Med; 2009 Jun; 360(24):2516-27. PubMed ID: 19516032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACP Journal Club. Periodic screening with prostate-specific antigen testing reduced mortality from prostate cancer.
    Canfield SE
    Ann Intern Med; 2009 Jun; 150(12):JC6-5, JC6-4. PubMed ID: 19528550
    [No Abstract]   [Full Text] [Related]  

  • 14. ACP Journal Club. Population-based screening using prostate-specific antigen testing reduced prostate cancer mortality.
    Hoffman RM
    Ann Intern Med; 2010 Dec; 153(12):JC6-9. PubMed ID: 21173410
    [No Abstract]   [Full Text] [Related]  

  • 15. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
    Kollmeier MA; Zelefsky MJ
    Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
    Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.
    Teloken PE; Ohebshalom M; Mohideen N; Mulhall JP
    J Urol; 2007 Dec; 178(6):2521-5. PubMed ID: 17937948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
    Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
    Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
    BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Androgen deprivation therapy in locally advanced prostate cancer].
    Rossi D; Beuzeboc P; Staerman F; Timsit MO; Benchikh El Fegoun A
    Prog Urol; 2010 Mar; 20 Suppl 1():S68-71. PubMed ID: 20493450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.